Informed Prostate Cancer Patient Support

‘We need more compassion’: UK families call for assisted dying reform | Assisted dying | The Guardian theguardian.com Harriet Sherwood A ccording to his son, for the 10 years after Norman Ward was diagnosed with prostate cancer at the age of 60, “you wouldn’t have known he was unwell”. But eventually, the cancer “spread everywhere”. Then he had a stroke. “It was all going wrong,” said Gareth Ward of his father. “He had been very independent. As long as he could go down the pub and walk his dog, he was happy. But he was in an awful lot of pain for a long time. He got thinner and weaker, and he had to take morphine all the time. He looked like he was already dead, and no one had told him.” One day, Norman called his son and said he couldn’t have another night like the one that had just passed. “He was very matter of fact, and said he was going to shoot hims

A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - ScienceDirect sciencedirect.com INTRODUCTION Isolated local failure (LF) after definitive radiotherapy for prostate cancer has the potential to significantly impact long-term disease-specific survival [1, 2]. Prior prospective trials have reported heterogeneous long-term rates of LF from approximately 1% [3] to 30%[4]. In part, this heterogeneity is explained by both the poor sensitivity of clinical examination and the poor specificity of a post-treatment biopsy to diagnose local failure, especially at early post-treatment timepoints[5]. In addition, treatment factors such as the receipt of androgen deprivation therapy (ADT)[6] and radiation dose[4, 7] have also been shown to substantially impact the rate of LF. As a result of rapid dose fall off, brachytherapy allows for the delivery of h

Study offers hope in identifying high-risk prostate cancer patients | Prostate cancer | The Guardian theguardian.com Nicola Davis The most common type of prostate cancer has two distinct ways of developing in the body, researchers have found, opening up new possibilities for identifying which patients need treatment. Prostate cancer is the most common form of cancer in men, with one in eight diagnosed with the disease during their lifetime . Most prostate cancers are adenocarcinomas – a type of cancer that forms in the glandular tissue that lines certain internal organs. But while the disease can kill, for many patients the risk is low. “The key problem in prostate cancer is identifying those 15% of men who will have more aggressive cancers that will spread to other organs and that will actually cause death,” said Prof David Wedge of Manchester Cancer Res

Study Tests Office-Based Transperineal Approach to Prostate Biopsies | MedPage Today medpagetoday.com Meeting Coverage > GuCS Video Pearls — Antibiotic-free option resulted in zero infections in randomized trial by Greg Laub , Director, Video, MedPage Today February 29, 2024 A multicenter randomized trial compared transperineal prostate biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis, examining infections, prostate cancer detection, pain, and other measures . The findings were presented at the recent Genitourinary Cancers Symposium opens in a new tab or window .

Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM - ScienceDirect sciencedirect.com Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM JL Mohler, ES Antonarakis, AJ Armstrong, et al. 40–51 minutes https://doi.org/10.1016/j.ijrobp.2024.02.025 Get rights and content Abstract Purpose: Recent experimental studies and clinical trial results might indicate that - at least for some indications - continued use of the mechanistic model for relative biological effectiveness (RBE) applied at carbon ion therapy facilities in Europe for several decades (LEM-I) may be unwarranted. We present a novel clinical framework for prostate cancer treatment planning and tumor control probability (TCP)